Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + irinotecan + fluorouracil
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Sintilimab (IBI308) is a recombinant human IgG4 monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor activity. In this combination therapy, it is paired with irinotecan, a topoisomerase I inhibitor, and 5-fluorouracil (5-FU), an antimetabolite that inhibits thymidylate synthase. This chemo-immunotherapy regimen is being developed by Innovent Biologics, in collaboration with Eli Lilly, for the treatment of various advanced malignancies, including non-small cell lung cancer and gastrointestinal cancers. The combination aims to leverage the cytotoxic effects of chemotherapy to enhance the immune-mediated response of the checkpoint inhibitor.
- Brand names
- Tyvyt
- Other names
- Sintilimab + irinotecan + 5-FUSintilimab + irinotecan + 5-fluorouracil
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on sintilimab + irinotecan + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + irinotecan + fluorouracil.